Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7820200
SERIAL NO

11575016

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a substained release form of hydralazine for use in cancer therapy. The substained release form of hydralazine can be used to obtain a constant concentration of the active principle in the blood, thereby enabling the demethylating effect of the hydralazine without producing the hypotensive action thereof, such that the inventive composition can be used in cancer therapy.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • PSICOFARMA, S.A. DE C.V.

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Betancourt, Alejandro Mohar Calzada de Tlalpan 4369 1 0
Flores, Luis Estrada Calzada de Tlalpan 4369 2 0
García, Arturo Borbolla Calzada de Tlalpan 4369 1 0
González, Alfonso Dueñas Calzada de Tlalpan 4369 1 0
Hernández, Alfredo Rivera Calzada de Tlalpan 4369 1 0
Martinez, Raul Serna Calzada de Tlalpan 4369 1 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation